



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Arlene H. Sharpe et al.

Serial No.: 08/702,525

Filed: August 30, 1996

For: NOVEL FORMS OF T CELL
COSTIMULATORY MOLECULES AND USES
THEREFOR

Attorney Docket No.: BWI-120CPUS

Group Art Unit: 1806

Examiner: P. Gambel

#10/a
C. A. West
1/6/98

Assistant Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

December 16, 1997

Date of Signature and of Mail Deposit

By: 

Amy E. Mandragouras
Reg. No. 38,207
Attorney for Applicant

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is a response to the Office Action mailed from the Patent Office on July 22, 1997 and the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures. A separate petition for an extension of time is being filed concurrently herewith.

Please amend the above-referenced application as follows: